El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 

Formulation Strategies to Improve Nose-to-Brain Delivery of Donepezil

dc.contributor.authorEspinoza, Lupe Carolina
dc.contributor.authorSilva Abreu, Marcelle
dc.contributor.authorClares Naveros, Beatriz
dc.contributor.authorRodríguez Lagunas, María José
dc.contributor.authorHalbaut, Lyda
dc.contributor.authorCañas Pacheco, María Alexandra
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.date.accessioned2020-04-15T12:11:29Z
dc.date.available2020-04-15T12:11:29Z
dc.date.issued2019-02-01
dc.date.updated2020-04-15T12:11:29Z
dc.description.abstractDonepezil (DPZ) is widely used in the treatment of Alzheimer's disease in tablet form for oral administration. The pharmacological efficacy of this drug can be enhanced by the use of intranasal administration because this route makes bypassing the blood-brain barrier (BBB) possible. The aim of this study was to develop a nanoemulsion (NE) as well as a nanoemulsion with a combination of bioadhesion and penetration enhancing properties (PNE) in order to facilitate the transport of DPZ from nose-to-brain. Composition of NE was established using three pseudo-ternary diagrams and PNE was developed by incorporating Pluronic F-127 to the aqueous phase. Parameters such as physical properties, stability, in vitro release profile, and ex vivo permeation were determined for both formulations. The tolerability was evaluated by in vitro and in vivo models. DPZ-NE and DPZ-PNE were transparent, monophasic, homogeneous, and physically stable with droplets of nanometric size and spherical shape. DPZ-NE showed Newtonian behavior whereas a shear thinning (pseudoplastic) behavior was observed for DPZ-PNE. The release profile of both formulations followed a hyperbolic kinetic. The permeation and prediction parameters were significantly higher for DPZ-PNE, suggesting the use of polymers to be an effective strategy to improve the bioadhesion and penetration of the drug through nasal mucosa, which consequently increase its bioavailability.
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec691103
dc.identifier.issn1999-4923
dc.identifier.pmid30717264
dc.identifier.urihttps://hdl.handle.net/2445/155359
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11020064
dc.relation.ispartofPharmaceutics, 2019, vol. 11, num. 2, p. 64
dc.relation.urihttps://doi.org/10.3390/pharmaceutics11020064
dc.rightscc-by (c) Espinoza, Lupe Carolina et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationMalaltia d'Alzheimer
dc.subject.classificationBarrera hematoencefàlica
dc.subject.classificationNeurofarmacologia
dc.subject.classificationCervell
dc.subject.otherAlzheimer's disease
dc.subject.otherBlood-brain barrier
dc.subject.otherNeuropharmacology
dc.subject.otherBrain
dc.titleFormulation Strategies to Improve Nose-to-Brain Delivery of Donepezil
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
691103.pdf
Mida:
5.12 MB
Format:
Adobe Portable Document Format